Sec Form 3 Filing - Rooney Timothy @ Avita Therapeutics, Inc. - 2020-06-30

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Rooney Timothy 2. Issuer Name and Ticker or Trading Symbol Avita Therapeutics, Inc. [ RCEL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Administrative Officer (Last) (First) (Middle) C/O AVITA THERAPEUTICS, INC., 28159 AVENUE STANFORD, SUITE 220 3. Date of Earliest Transaction (MM/DD/YY) 06/30/2020 (Street) VALENCIA, CA91355 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 2,500 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (Right to Buy) ( 2 ) $ 6.34 ( 4 ) ( 3 ) 05/18/2027 Common Stock 2,500 D Stock Options (Right to Buy) ( 2 ) $ 6.35 ( 6 ) ( 5 ) 11/01/2028 Common Stock 3,750 D Stock Options (Right to Buy) ( 2 ) $ 5.99 ( 8 ) ( 7 ) 11/30/2028 Common Stock 28,350 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Rooney Timothy C/O AVITA THERAPEUTICS, INC. 28159 AVENUE STANFORD, SUITE 220 VALENCIA, CA91355 Chief Administrative Officer Signatures /s/ Donna Shiroma, by power of attorney 07/10/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes 12,500 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of theIssuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, asubsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rightsand privileges of Common Stock. The Reporting Person holds 12,500 CDIs, which translate into 2,500 of the shares of Common Stock setforth above. ( 2 )These Stock Options were originally exercisable for ordinary shares of Avita Medical, Ltd. ("Predecessor"). Pursuant to the scheme arrangement completed on June 30, 2020, the Stock Options becameexercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessorfor which the Stock Options would otherwise be exercisable. ( 3 )These Stock Options become exercisable in five equal annual installments beginning on May 18, 2017. ( 4 )The exercise price was converted from A$8.5, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor toshares of the Issuer's Common Stock, using the exchange rate as in effect on the date of grant (May 18, 2017). The actual exercise price will be the Australiandollar amount regardless of the exchange rate on the date of grant or of exercise. ( 5 )These Stock Options become exercisable in four equal annual installments beginning on November 1, 2019. ( 6 )The exercise price was converted from A$8.9, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as in effect on the date of grant (November 1, 2018). The actual exercise price will be the Australian dollar amount regardless of the exchange rate on the date of grant or of exercise. ( 7 )These Stock Options become exercisable in four equal annual installments beginning on November 30, 2019. ( 8 )The exercise price was converted from A$8.2, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as in effect on the date of grant (November 30, 2018). The actual exercise price will be the Australian dollar amount regardless of the exchange rate on the date of grant or of exercise.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.